JP2012515225A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515225A5
JP2012515225A5 JP2011546409A JP2011546409A JP2012515225A5 JP 2012515225 A5 JP2012515225 A5 JP 2012515225A5 JP 2011546409 A JP2011546409 A JP 2011546409A JP 2011546409 A JP2011546409 A JP 2011546409A JP 2012515225 A5 JP2012515225 A5 JP 2012515225A5
Authority
JP
Japan
Prior art keywords
benzo
optionally substituted
pyridazin
triazole
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011546409A
Other languages
English (en)
Japanese (ja)
Other versions
JP5858789B2 (ja
JP2012515225A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/021275 external-priority patent/WO2010083465A1/en
Publication of JP2012515225A publication Critical patent/JP2012515225A/ja
Publication of JP2012515225A5 publication Critical patent/JP2012515225A5/ja
Application granted granted Critical
Publication of JP5858789B2 publication Critical patent/JP5858789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011546409A 2009-01-16 2010-01-15 転移性癌の予防、治療、または管理のための併用療法に用いるためのaxl阻害薬 Active JP5858789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14544809P 2009-01-16 2009-01-16
US61/145,448 2009-01-16
PCT/US2010/021275 WO2010083465A1 (en) 2009-01-16 2010-01-15 Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014208912A Division JP2015007135A (ja) 2009-01-16 2014-10-10 転移性癌の予防、治療、または管理のための併用療法に用いるためのaxl阻害薬

Publications (3)

Publication Number Publication Date
JP2012515225A JP2012515225A (ja) 2012-07-05
JP2012515225A5 true JP2012515225A5 (cg-RX-API-DMAC7.html) 2013-02-28
JP5858789B2 JP5858789B2 (ja) 2016-02-10

Family

ID=41683427

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011546409A Active JP5858789B2 (ja) 2009-01-16 2010-01-15 転移性癌の予防、治療、または管理のための併用療法に用いるためのaxl阻害薬
JP2014208912A Pending JP2015007135A (ja) 2009-01-16 2014-10-10 転移性癌の予防、治療、または管理のための併用療法に用いるためのaxl阻害薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014208912A Pending JP2015007135A (ja) 2009-01-16 2014-10-10 転移性癌の予防、治療、または管理のための併用療法に用いるためのaxl阻害薬

Country Status (13)

Country Link
US (5) US8546433B2 (cg-RX-API-DMAC7.html)
EP (1) EP2387395B1 (cg-RX-API-DMAC7.html)
JP (2) JP5858789B2 (cg-RX-API-DMAC7.html)
CN (1) CN102281875B (cg-RX-API-DMAC7.html)
AU (1) AU2010204578B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1007046B1 (cg-RX-API-DMAC7.html)
CA (1) CA2749843C (cg-RX-API-DMAC7.html)
ES (1) ES2528032T3 (cg-RX-API-DMAC7.html)
PL (1) PL2387395T3 (cg-RX-API-DMAC7.html)
PT (1) PT2387395E (cg-RX-API-DMAC7.html)
RU (1) RU2555326C2 (cg-RX-API-DMAC7.html)
SG (1) SG172997A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010083465A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621503C (en) * 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
PT2114955E (pt) 2006-12-29 2013-04-18 Rigel Pharmaceuticals Inc Triazoles substituídos com arilo bicíclico em ponte ou heteroarilo bicíclico em ponte úteis como inibidores de axl
CA2710234C (en) 2006-12-29 2015-10-20 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
ES2607065T3 (es) * 2006-12-29 2017-03-29 Rigel Pharmaceuticals, Inc. Triazoles N3-heteroaril sustituidos y triazoles N5-heteroaril sustituidos útiles como inhibidores de axl
AU2007342007A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as Axl inhibitors
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2009054864A1 (en) * 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CN102007124B (zh) 2008-02-15 2014-06-18 里格尔制药公司 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途
EP2328888B1 (en) 2008-07-09 2012-11-07 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2326641B1 (en) 2008-07-09 2014-09-03 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP4644273B2 (ja) * 2008-07-15 2011-03-02 本田技研工業株式会社 車両周辺監視装置
SG172997A1 (en) * 2009-01-16 2011-08-29 Rigel Pharmaceuticals Inc Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
EP2484678B1 (en) 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
GB201207722D0 (en) 2012-05-02 2012-06-13 Bergenbio As Method
CA2879542A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
US9771333B2 (en) 2013-11-20 2017-09-26 Signalchem Lifesciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
AU2014354711B2 (en) 2013-11-27 2018-10-25 Signalchem Lifesciences Corporation Aminopyridine derivatives as TAM family kinase inhibitors
EP3076966A2 (en) * 2013-12-02 2016-10-12 BerGenBio AS Use of kinase inhibitors
US20170027940A1 (en) * 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
US10028958B2 (en) * 2014-04-19 2018-07-24 Massachusetts Institute Of Technology Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors
GB201420285D0 (en) 2014-11-14 2014-12-31 Bergenbio As Process
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
CN106083764B (zh) * 2016-07-11 2018-09-18 上海皓元生物医药科技有限公司 一种用于制备axl抑制剂的高纯度中间体的手性拆分方法
CN109384774B (zh) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
MX2020007130A (es) * 2017-11-04 2021-02-15 Aravive Biologics Inc Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
AU2019343044B2 (en) 2018-09-18 2025-03-06 Signalchem Lifesciences Corporation Combination therapy for treating blood cancer
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
TW202304908A (zh) * 2021-04-14 2023-02-01 日商衛材R&D企管股份有限公司 四氫吡啶并嘧啶化合物
GB202209285D0 (en) 2022-06-24 2022-08-10 Bergenbio Asa Dosage regimen for AXL inhibitor
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1403866A (en) 1971-12-06 1975-08-28 Wyeth John & Brother Ltd Derivatives of 3-amino-1,2,4-triazoles
US4512992A (en) 1980-06-13 1985-04-23 Burroughs Wellcome Co. Treatment with dialkoxy pyridopyrimidine compounds
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US6258360B1 (en) 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
EP0710654A4 (en) 1993-07-23 1996-08-28 Green Cross Corp TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
GB9918180D0 (en) 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
YU51803A (sh) 2000-12-22 2006-05-25 Ortho Mc Neil Pharmaceutical Inc. Supstituisani derivati triazol diamina kao inhibitori kinaza
DE10123586A1 (de) 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US7351729B2 (en) * 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
NZ536294A (en) 2002-05-03 2005-05-27 Janssen Pharmaceutica Nv Polymeric microemulsions of amphiphilic diblock copolymers
AU2003252395A1 (en) 2002-08-06 2004-03-11 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
AU2003286746A1 (en) 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
MXPA05009885A (es) 2003-03-14 2005-12-05 Astrazeneca Ab Nuevas triazolonas fusionadas y los usos de las mismas.
WO2004110986A1 (ja) 2003-06-12 2004-12-23 Astellas Pharma Inc. ベンズアミド誘導体又はその塩
WO2005013982A1 (en) 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
AU2005209485A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
BRPI0507634A (pt) 2004-02-11 2007-07-03 Janssen Pharmaceutica Nv processo para preparação de compostos triazóis substituìdos
EP1763514A2 (en) 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
MX2007001727A (es) 2004-08-13 2007-04-20 Genentech Inc Compuestos a base de 2-amido-tiazol que exhiben actividad inhibidora de enzima que utiliza atp y composiciones y usos de los mismos.
DE602005025655D1 (de) 2004-09-17 2011-02-10 Vertex Pharma Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen
NZ555088A (en) 2004-10-21 2009-08-28 Vertex Pharma N-[(4-cyclohexyl)-phenyl]-[1,2,4]triazole-3,5-diamines useful as inhibitors of protein kinases
WO2006050249A1 (en) 2004-10-29 2006-05-11 Vertex Pharmaceuticals Incorporated Diaminotriazole compounds useful as inhibitors of protein kinases
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CA2621503C (en) 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
EP1960372B1 (en) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
US8217037B2 (en) 2006-04-07 2012-07-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
FR2908131B1 (fr) 2006-11-03 2009-01-09 Univ Haute Alsace Etablissemen Derives d'aminobenzocycloheptene,leurs procedes de preparation et leur utilisation en therapeutique
JP2008130120A (ja) 2006-11-17 2008-06-05 Sharp Corp 光ピックアップ装置
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
PT2114955E (pt) 2006-12-29 2013-04-18 Rigel Pharmaceuticals Inc Triazoles substituídos com arilo bicíclico em ponte ou heteroarilo bicíclico em ponte úteis como inibidores de axl
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710234C (en) 2006-12-29 2015-10-20 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
ES2607065T3 (es) 2006-12-29 2017-03-29 Rigel Pharmaceuticals, Inc. Triazoles N3-heteroaril sustituidos y triazoles N5-heteroaril sustituidos útiles como inhibidores de axl
AU2007342007A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as Axl inhibitors
BRPI0813356A2 (pt) 2007-06-15 2014-12-30 Irm Llc Inibidores de proteína quinase e métodos para uso dos mesmos
WO2009054864A1 (en) 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CN102007124B (zh) 2008-02-15 2014-06-18 里格尔制药公司 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途
EP2326641B1 (en) 2008-07-09 2014-09-03 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2328888B1 (en) 2008-07-09 2012-11-07 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
SG172997A1 (en) 2009-01-16 2011-08-29 Rigel Pharmaceuticals Inc Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer

Similar Documents

Publication Publication Date Title
JP2012515225A5 (cg-RX-API-DMAC7.html)
RU2011132118A (ru) Ингибиторы axl для применения в комбинированной терапии для предотвращения, устранения или лечения метастизирующего рака
JP2020105211A5 (cg-RX-API-DMAC7.html)
JP7174735B2 (ja) (s)-3-(4-((4-(モルホリノメチル)ベンジル)オキシ)-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法
US10968235B2 (en) N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
EP3468972B1 (en) Compounds and compositions for inhibiting the activity of shp2
EP3310771B1 (en) Compounds and compositions for inhibiting the activity of shp2
AU2018358157B2 (en) Modulators of the integrated stress pathway
EP3094627B1 (en) 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
EP3310774B1 (en) Compounds and compositions for inhibiting the activity of shp2
EP3724178B1 (en) 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
CN105407889B (zh) 针对Rb阳性异常细胞增殖的HSPC节制性治疗
JP2017515802A5 (cg-RX-API-DMAC7.html)
JP2022141811A5 (cg-RX-API-DMAC7.html)
JP2016539138A5 (cg-RX-API-DMAC7.html)
CA2943022C (en) Benzo[g]pyrido[2,1-b] quinazoline carboxamide compounds which inhibit rna polymerase, compositions including such compounds, and their use
KR20210088584A (ko) 소분자 cd-47 저해제와 다른 항암제의 조합물
CA3056308A1 (en) Pharmaceutical compounds
CN110402141A (zh) Axl抑制剂和EGFR酪氨酸激酶抑制剂的联合疗法
JPWO2020257429A5 (cg-RX-API-DMAC7.html)
JP2022512874A (ja) 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用
CN111989092A (zh) Bet抑制剂和蛋白酶体抑制剂的联合治疗
JP2020528418A (ja) BET阻害剤及びBcl−2阻害剤を用いた併用療法
JPWO2021263205A5 (cg-RX-API-DMAC7.html)
HK40038452B (en) 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer